{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:07:29Z","timestamp":1785409649792,"version":"3.56.0"},"reference-count":56,"publisher":"IMR Press","issue":"7","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Cardiovasc. Med."],"abstract":"<jats:p>The early period following percutaneous coronary intervention (PCI), particularly the first days to weeks after stent implantation, is characterized by heightened device-related thrombotic risk, and dual antiplatelet therapy (DAPT) during this phase is well established. With contemporary drug-eluting stents (DES) and abbreviated DAPT strategies, late stent-related events have become less frequent, and long-term risk increasingly reflects underlying systemic atherosclerotic disease. Beyond 12 months, the risk profile shifts further: late events increasingly reflect progressive atherosclerosis and systemic vascular disease rather than stent-related thrombosis. This review synthesizes contemporary evidence on long-term antiplatelet and antithrombotic therapy after PCI, with a focus on the period beyond one year. We evaluate the data supporting for lifelong aspirin as the traditional default strategy, as well as the emerging evidence that P2Y12 inhibitor monotherapy may be superior to aspirin in selected post-PCI populations (HOST-EXAM, HOST-EXAM Extended, PANTHER, SMART-CHOICE 3). This review also examines the role of prolonged DAPT in selected high-risk patients (DAPT Trial, PEGASUS\u2013Thrombolysis in Myocardial Infarction (TIMI) 54) and the paradigm of dual-pathway inhibition with low-dose rivaroxaban plus aspirin (COMPASS, VOYAGER-peripheral artery disease (PAD)). In addition, the review considers protease-activated receptor (PAR) antagonism (TRA 2\u00b0P\u2013TIMI 50) and precision-based strategies, including CYP2C19 genotype-guided therapy. Special populations, such as patients with diabetes, chronic kidney disease (CKD), polyvascular disease, and those requiring concomitant oral anticoagulation, present distinct long-term management challenges. Thus, novel targets, including factor XIa inhibitors and PAR-4 antagonists, may further refine the antithrombotic approach. Overall, the optimal long-term strategy after PCI is increasingly defined not by fixed timelines but by the dynamic balance between ischemic and bleeding risk.<\/jats:p>","DOI":"10.31083\/rcm51947","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T10:31:43Z","timestamp":1785407503000},"source":"Crossref","is-referenced-by-count":0,"title":["Long-Term Antithrombotic Therapy After Percutaneous Coronary Intervention: Secondary Prevention Beyond One Year"],"prefix":"10.31083","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-9030-6272","authenticated-orcid":true,"given":"Mohamed","family":"Abdelgader","sequence":"first","affiliation":[{"name":"Department of Cardiology, Leeds Teaching Hospitals NHS Trust, LS1 3EX Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4863-5801","authenticated-orcid":true,"given":"Roann","family":"Khalid","sequence":"additional","affiliation":[{"name":"General Medicine, King\u2019s College Hospital NHS Foundation Trust, SE5 9RS London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0380-7298","authenticated-orcid":true,"given":"Kartik","family":"Yadav","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Leeds Teaching Hospitals NHS Trust, LS1 3EX Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8760-3723","authenticated-orcid":true,"given":"Sama Ehab Salah","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Leeds Teaching Hospitals NHS Trust, LS1 3EX Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6456-1296","authenticated-orcid":true,"given":"Murugapathy","family":"Veerasamy","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Leeds Teaching Hospitals NHS Trust, LS1 3EX Leeds, UK"},{"name":"Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, LS2 9JT Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1134-3036","authenticated-orcid":true,"given":"Arka","family":"Das","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Leeds Teaching Hospitals NHS Trust, LS1 3EX Leeds, UK"},{"name":"Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, LS2 9JT Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1985-1783","authenticated-orcid":true,"given":"Heerajnarain","family":"Bulluck","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Leeds Teaching Hospitals NHS Trust, LS1 3EX Leeds, UK"},{"name":"Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, LS2 9JT Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. The New England Journal of Medicine. 2001; 345: 494\u2013502.","DOI":"10.1056\/NEJMoa010746"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Steinhubl SR, Berger PB, Mann JT 3rd, Fry ETA, DeLago A, Wilmer C, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002; 288: 2411\u20132420.","DOI":"10.1001\/jama.288.19.2411"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. The New England Journal of Medicine. 2014; 371: 2155\u20132166.","DOI":"10.1056\/NEJMoa1409312"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Collet JP, Thiele H, Barbato E, Barth\u00e9l\u00e9my O, Bauersachs J, Bhatt DL, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal. 2021; 42: 1289\u20131367.","DOI":"10.1093\/eurheartj\/ehaa575"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, et al. A prospective natural-history study of coronary atherosclerosis. The New England Journal of Medicine. 2011; 364: 226\u2013235.","DOI":"10.1056\/NEJMoa1002358"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Mehran R, Baber U, Steg PG, Ariti C, Weisz G, Witzenbichler B, et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet (London, England). 2013; 382: 1714\u20131722.","DOI":"10.1016\/S0140-6736(13)61720-1"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"G\u00e9n\u00e9reux P, Giustino G, Witzenbichler B, Weisz G, Stuckey TD, Rinaldi MJ, et al. Incidence, Predictors, and Impact of Post-Discharge Bleeding After Percutaneous Coronary Intervention. Journal of the American College of Cardiology. 2015; 66: 1036\u20131045.","DOI":"10.1016\/j.jacc.2015.06.1323"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation. 2007; 115: 1440\u201355; discussion 1455.","DOI":"10.1161\/CIRCULATIONAHA.106.666800"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. Journal of the American College of Cardiology. 2006; 48: 2584\u20132591.","DOI":"10.1016\/j.jacc.2006.10.026"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Palmerini T, Biondi-Zoccai G, Della Riva D, Mariani A, Sabat\u00e9 M, Smits PC, et al. Clinical outcomes with bioabsorbable polymer- versus durable polymer-based drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Journal of the American College of Cardiology. 2014; 63: 299\u2013307.","DOI":"10.1016\/j.jacc.2013.09.061"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Bhatt DL, Eagle KA, Ohman EM, Hirsch AT, Goto S, Mahoney EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. 2010; 304: 1350\u20131357.","DOI":"10.1001\/jama.2010.1322"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. European Heart Journal. 2015; 36: 1163\u20131170.","DOI":"10.1093\/eurheartj\/ehu505"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ (Clinical Research Ed.). 2002; 324: 71\u201386.","DOI":"10.1136\/bmj.324.7329.71"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet (London, England). 1996; 348: 1329\u20131339.","DOI":"10.1016\/s0140-6736(96)09457-3"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Koo BK, Kang J, Park KW, Rhee TM, Yang HM, Won KB, et al. Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial. Lancet (London, England). 2021; 397: 2487\u20132496.","DOI":"10.1016\/S0140-6736(21)01063-1"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Kang J, Park KW, Lee H, Hwang D, Yang HM, Rha SW, et al. Aspirin Versus Clopidogrel for Long-Term Maintenance Monotherapy After Percutaneous Coronary Intervention: The HOST-EXAM Extended Study. Circulation. 2023; 147: 108\u2013117.","DOI":"10.1161\/CIRCULATIONAHA.122.062770"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Kang J, Park S, Yang HM, Shin ES, Rha SW, Bae JW, et al. Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention: 10-year follow-up of the HOST-EXAM trial. Lancet (London, England). 2026; 407: 1439\u20131447.","DOI":"10.1016\/S0140-6736(26)00422-8"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Choi KH, Park YH, Lee JY, Jeong JO, Kim CJ, Yun KH, et al. Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention (SMART-CHOICE 3): a randomised, open-label, multicentre trial. Lancet (London, England). 2025; 405: 1252\u20131263.","DOI":"10.1016\/S0140-6736(25)00449-0"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Gragnano F, Cao D, Pirondini L, Franzone A, Kim HS, von Scheidt M, et al. P2Y12 Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events. Journal of the American College of Cardiology. 2023; 82: 89\u2013105.","DOI":"10.1016\/j.jacc.2023.04.051"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Giacoppo D, Gragnano F, Watanabe H, Kimura T, Kang J, Park KW, et al. P2Y12 inhibitor or aspirin after percutaneous coronary intervention: individual patient data meta-analysis of randomised clinical trials. BMJ (Clinical Research Ed.). 2025; 389: e082561.","DOI":"10.1136\/bmj-2024-082561"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Valgimigli M, Choi KH, Giacoppo D, Gragnano F, Kimura T, Watanabe H, et al. Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis. Lancet (London, England). 2025; 406: 1091\u20131102.","DOI":"10.1016\/S0140-6736(25)01562-4"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clinical Pharmacology and Therapeutics. 2013; 94: 317\u2013323.","DOI":"10.1038\/clpt.2013.105"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. The New England Journal of Medicine. 2015; 372: 1791\u20131800.","DOI":"10.1056\/NEJMoa1500857"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Yeh RW, Secemsky EA, Kereiakes DJ, Normand SLT, Gershlick AH, Cohen DJ, et al. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. JAMA. 2016; 315: 1735\u20131749.","DOI":"10.1001\/jama.2016.3775"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. The New England Journal of Medicine. 2017; 377: 1319\u20131330.","DOI":"10.1056\/NEJMoa1709118"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Anand SS, Eikelboom JW, Dyal L, Bosch J, Neumann C, Widimsky P, et al. Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial. Journal of the American College of Cardiology. 2019; 73: 3271\u20133280.","DOI":"10.1016\/j.jacc.2019.02.079"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Bonaca MP, Bauersachs RM, Anand SS, Debus ES, Nehler MR, Patel MR, et al. Rivaroxaban in Peripheral Artery Disease after Revascularization. The New England Journal of Medicine. 2020; 382: 1994\u20132004.","DOI":"10.1056\/NEJMoa2000052"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal. 2020; 41: 407\u2013477.","DOI":"10.1093\/eurheartj\/ehz425"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. European Heart Journal. 2024; 45: 3415\u20133537.","DOI":"10.1093\/eurheartj\/ehae177"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, et al. Vorapaxar in the secondary prevention of atherothrombotic events. The New England Journal of Medicine. 2012; 366: 1404\u20131413.","DOI":"10.1056\/NEJMoa1200933"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Steg PG, Bhatt DL, Simon T, Fox K, Mehta SR, Harrington RA, et al. Ticagrelor in Patients with Stable Coronary Disease and Diabetes. The New England Journal of Medicine. 2019; 381: 1309\u20131320.","DOI":"10.1056\/NEJMoa1908077"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Bhatt DL, Steg PG, Mehta SR, Leiter LA, Simon T, Fox K, et al. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. Lancet (London, England). 2019; 394: 1169\u20131180.","DOI":"10.1016\/S0140-6736(19)31887-2"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Ferreiro JL, Angiolillo DJ. Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation. 2011; 123: 798\u2013813.","DOI":"10.1161\/CIRCULATIONAHA.109.913376"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Lutz J, Menke J, Sollinger D, Schinzel H, Th\u00fcrmel K. Haemostasis in chronic kidney disease. Nephrology, Dialysis, Transplantation. 2014; 29: 29\u201340.","DOI":"10.1093\/ndt\/gft209"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006; 295: 180\u2013189.","DOI":"10.1001\/jama.295.2.180"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Roe MT, Goodman SG, Ohman EM, Stevens SR, Hochman JS, Gottlieb S, et al. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel. Circulation. 2013; 128: 823\u2013833.","DOI":"10.1161\/CIRCULATIONAHA.113.002303"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, et al. Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. The New England Journal of Medicine. 2019; 381: 1103\u20131113.","DOI":"10.1056\/NEJMoa1904143"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, et al. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. The New England Journal of Medicine. 2019; 380: 1509\u20131524.","DOI":"10.1056\/NEJMoa1817083"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Gragnano F, Giacoppo D, Choi KH, Kimura T, Watanabe H, Kim HS, et al. Clopidogrel Versus Aspirin Monotherapy in Coronary Artery Disease: A Sex-Stratified Individual Patient Data Meta-Analysis of Randomized Trials. Circulation. 2026; 153: 543\u2013546.","DOI":"10.1161\/CIRCULATIONAHA.126.079221"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Claassens DMF, Vos GJA, Bergmeijer TO, Hermanides RS, van 't Hof AWJ, van der Harst P, et al. A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI. The New England Journal of Medicine. 2019; 381: 1621\u20131631.","DOI":"10.1056\/NEJMoa1907096"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Pereira NL, Farkouh ME, So D, Lennon R, Geller N, Mathew V, et al. Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial. JAMA. 2020; 324: 761\u2013771.","DOI":"10.1001\/jama.2020.12443"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Collet JP, Cuisset T, Rang\u00e9 G, Cayla G, Elhadad S, Pouillot C, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. The New England Journal of Medicine. 2012; 367: 2100\u20132109.","DOI":"10.1056\/NEJMoa1209979"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Costa F, van Klaveren D, James S, Heg D, R\u00e4ber L, Feres F, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet (London, England). 2017; 389: 1025\u20131034.","DOI":"10.1016\/S0140-6736(17)30397-5"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. European Heart Journal. 2019; 40: 2632\u20132653.","DOI":"10.1093\/eurheartj\/ehz372"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Gragnano F, van Klaveren D, Heg D, R\u00e4ber L, Krucoff MW, Raposeiras-Roub\u00edn S, et al. Derivation and Validation of the PRECISE-HBR Score to Predict Bleeding After Percutaneous Coronary Intervention. Circulation. 2025; 151: 343\u2013355.","DOI":"10.1161\/CIRCULATIONAHA.124.072009"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Fredenburgh JC, Weitz JI. Factor XI as a Target for New Anticoagulants. Hamostaseologie. 2021; 41: 104\u2013110.","DOI":"10.1055\/a-1384-3715"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Sharma M, Dong Q, Hirano T, Kasner SE, Saver JL, Masjuan J, et al. Asundexian for Secondary Stroke Prevention. The New England journal of medicine. 2026; 394: 1467\u20131479.","DOI":"10.1056\/NEJMoa2513880"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Piccini JP, Patel MR, Steffel J, Ferdinand K, Van Gelder IC, Russo AM, et al. Asundexian versus Apixaban in Patients with Atrial Fibrillation. The New England journal of medicine. 2025; 392: 23\u201332.","DOI":"10.1056\/NEJMoa2407105"},{"key":"ref49","unstructured":"Bristol-Myers Squibb. Update on Phase 3 Librexia-ACS trial (sponsor press release). 2025. Available at: https:\/\/news.bms.com\/news\/details\/2025\/Update-on-Phase-3-Librexia-ACS-Trial\/ (Accessed: 12 March 2026)."},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Wilson SJ, Ismat FA, Wang Z, Cerra M, Narayan H, Raftis J, et al. PAR4 (Protease-Activated Receptor 4) Antagonism With BMS-986120 Inhibits Human Ex Vivo Thrombus Formation. Arteriosclerosis, Thrombosis, and Vascular Biology. 2018; 38: 448\u2013456.","DOI":"10.1161\/ATVBAHA.117.310104"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Storey RF, Gurbel PA, Ten Berg J, Bernaud C, Dangas GD, Frenoux JM, et al. Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes. European Heart Journal. 2020; 41: 3132\u20133140.","DOI":"10.1093\/eurheartj\/ehz807"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Ali ZA, Maehara A, G\u00e9n\u00e9reux P, Shlofmitz RA, Fabbiocchi F, Nazif TM, et al. Optical coherence tomography compared with intravascular ultrasound and with angiography to guide coronary stent implantation (ILUMIEN III: OPTIMIZE PCI): a randomised controlled trial. Lancet (London, England). 2016; 388: 2618\u20132628.","DOI":"10.1016\/S0140-6736(16)31922-5"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Mayer K, Hein-Rothweiler R, Sch\u00fcpke S, Janisch M, Bernlochner I, Ndrepepa G, et al. Efficacy and Safety of Revacept, a Novel Lesion-Directed Competitive Antagonist to Platelet Glycoprotein VI, in Patients Undergoing Elective Percutaneous Coronary Intervention for Stable Ischemic Heart Disease: The Randomized, Double-blind, Placebo-Controlled ISAR-PLASTER Phase 2 Trial. JAMA Cardiology. 2021; 6: 753\u2013761.","DOI":"10.1001\/jamacardio.2021.0475"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Pottecher J, Raffi F, Jandrot-Perrus M, Binay S, Comenducci A, Desort-Henin V, et al. Targeting GPVI with glenzocimab in COVID-19 patients: Results from a randomized clinical trial. PloS One. 2024; 19: e0302897.","DOI":"10.1371\/journal.pone.0302897"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Lee SY, Jeong YH, Yun KH, Cho JY, Gorog DA, Angiolillo DJ, et al. P2Y12 Inhibitor Monotherapy Combined With Colchicine Following PCI in ACS Patients: The MACT Pilot Study. JACC. Cardiovascular Interventions. 2023; 16: 1845\u20131855.","DOI":"10.1016\/j.jcin.2023.05.035"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Mourikis P, Benkhoff M, Wildeis L, Barcik M, Helten C, Coman C, et al. Icosapent ethyl reduces arterial thrombosis by inhibition of cyclooxygenase-1-induced platelet reactivity. Science Translational Medicine. 2025; 17: eado0610.","DOI":"10.1126\/scitranslmed.ado0610"}],"container-title":["Reviews in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/27\/7\/10.31083\/RCM51947","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T10:32:02Z","timestamp":1785407522000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/27\/7\/10.31083\/RCM51947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":56,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"alternative-id":["S1530-6550(26)03361-0"],"URL":"https:\/\/doi.org\/10.31083\/rcm51947","relation":{},"ISSN":["1530-6550","2153-8174"],"issn-type":[{"value":"1530-6550","type":"print"},{"value":"2153-8174","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"article-number":"51947"}}